Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

The new medicine (branded as Ryzodeg) is a combination of two other medicines: insulin degludec (an ultra-long-acting insulin) and insulin aspart (a rapid-acting insulin). If the funding proposal ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

while insulin glargine and insulin degludec have side effects that mean some patients are unable to take them. Novo Nordisk has been selling Levemir in the US for nearly 20 years, and in March ...

MannKind Corporation announced that it will present data from five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

Type 2 diabetes progresses from an early asymptomatic state with insulin resistance, to mild postprandial hyperglycemia, to clinical diabetes requiring pharmacological intervention due to ...

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.